Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v3-FR | Version v3-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2024-05-15 | 2024-05-15 |
| Drug Identification Number | 00707937 | 00707937 |
| Brand name | EYE STREAM | EYE STREAM |
| Common or Proper name | EYE STREAM | EYE STREAM |
| Company Name | ALCON CANADA INC | ALCON CANADA INC |
| Ingredients | MAGNESIUM CHLORIDE CALCIUM CHLORIDE POTASSIUM CHLORIDE SODIUM CHLORIDE | MAGNESIUM CHLORIDE CALCIUM CHLORIDE POTASSIUM CHLORIDE SODIUM CHLORIDE |
| Strength(s) | 0.03% 0.048% 0.075% 0.64% | 0.03% 0.048% 0.075% 0.64% |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | OPHTHALMIC OPHTHALMIC | OPHTHALMIC OPHTHALMIC |
| Packaging size | 30 ml and 118 ml | 30 ml and 118 ml |
| ATC code | V07AB | V07AB |
| ATC description | ALL OTHER NON-THERAPEUTIC PRODUCTS | ALL OTHER NON-THERAPEUTIC PRODUCTS |
| Reason for discontinuation | Other (Please describe in comments) | Other (Please describe in comments) |
| Anticipated discontinuation date | 2022-10-31 | 2022-10-31 |
| Actual discontinuation date | 2022-10-25 | 2022-10-25 |
| Remaining supply date | 2022-10-25 | 2022-10-25 |
| Discontinuation status | Discontinued | Discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | Last lot Expiration in Market is Jan 2025 ( Eyestream 30 ml) and May 2025 ( Eyestream 118 ml). | Last lot Expiration in Market is Jan 2025 ( Eyestream 30 ml) and May 2025 ( Eyestream 118 ml). |
| Health Canada comments |